Aethlon Medical (NASDAQ:AEMD) Shares Break Below 200 Day Moving Average – What’s Next?

Shares of Aethlon Medical, Inc. (NASDAQ:AEMD) passed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $7.19 and traded as low as $6.36. Aethlon Medical shares last traded at $6.77, with a volume of 149,951 shares traded.

Analysts Set New Price Targets

AEMD has been the subject of a number of recent research reports. HC Wainwright reiterated a “neutral” rating on shares of Aethlon Medical in a research note on Friday, September 18th. Wall Street Zen upgraded shares of Aethlon Medical to a “sell” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research report on Friday, July 17th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $1.50.

Aethlon Medical Price Performance

The stock has a 50-day moving average price of $3.10 and a 200 day moving average price of $7.18. The firm has a market cap of $4.46 million, a price-to-earnings ratio of -0.18 and a beta of 1.40.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.92) by ($0.10). As a group, equities research analysts predict that Aethlon Medical, Inc. will post -5.74 earnings per share for the current year.

Aethlon Medical Company Profile

Aethlon Medical, Inc is a clinical-stage medical device company focused on developing therapeutic technologies for cancer and life-threatening viral infections. The company’s lead product is the Hemopurifier, an investigational extracorporeal blood filtration device designed to selectively remove certain disease-causing particles, including tumor-derived exosomes and viruses, from the bloodstream.

The Hemopurifier is being evaluated as a potential adjunct to existing treatments. In oncology, the technology is intended to remove exosomes that may contribute to tumor progression and immune suppression.